Journals / BEYOGLU EYE JOURNAL / 2018 / Cilt: 3 - Sayı: 2

Effects of Intravitreal Injection of Ranibizumab and Aflibercept on Corneal Endothelium and Central Corneal Thickness

Pages
86–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the IVR group, a statistically significant difference was seen in terms of the HEX values.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study was an evaluation of intravitreal injections of ranibizumab (IVR) and aflibercept (IVA) administered to the corneal endothelium.
📊
Key Findings & Data:Methods: Thirty eyes of 30 patients made up the IVR injection group and 30 eyes of another 30 patients were recruited as the IVA injection group.
💡
Conclusion & Impact:In the IVR group, a statistically significant difference was seen in terms of the HEX values.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study was an evaluation of intravitreal injections of ranibizumab (IVR) and aflibercept (IVA) administered to the corneal endothelium. Methods: Thirty eyes of 30 patients made up the IVR injection group and 30 eyes of another 30 patients were recruited as the IVA injection group. Specular microscopy results before the injection, on the 1st, 7th, and 30th days were examined. Central corneal thickness (CCT), endothelial cell density (CD), coefficient of variation (CV), and hexagonality (HEX) values were recorded. Results: No difference was seen between the groups with respect to gender (p=0.057). No significant difference was seen in CCT measurements in the IVR or the IVA group (p=0.08, p=0.16, respectively). Nor was a significant difference seen in the IVR group in terms of CD (p=0.85); however, a statistically significant difference was detected in the IVA group (p=0.03). Furthermore, no significant difference was seen in the IVR or the IVA group with regard to CV (p=0.12, p=0.17, respectively), and no significant difference was seen in the IVA group with respect to HEX values between measurements intervals (p>0.05); however, a significant difference was found in the IVR group (p=0.02). Conclusion: Neither IVR nor IVA affected the CCT or CV values. The CD did not change significantly in the IVR group, whereas in the IVA group, the CD values of the first day after the injection were high, although they had returned to normal on the 30th day. In the IVR group, a statistically significant difference was seen in terms of the HEX values.

🔖

Cite This Article

COŞKUN, M. (2018). Effects of Intravitreal Injection of Ranibizumab and Aflibercept on Corneal Endothelium and Central Corneal Thickness. BEYOGLU EYE JOURNAL, Cilt: 3 - Sayı: 2, 86–90. https://ajindex.com/articles/147267

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012;181:376–9. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660–8. [CrossRef] Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557–63. [CrossRef] Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, et al. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 2013;97:28–32. [CrossRef] Chalam KV, Agarwal S, Brar VS, Murthy RK, Sharma RK. Evaluation of cytotoxic effects of bevacizumab on human corneal cells. Cornea 2009;28:328–33. [CrossRef] Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569–78.
  2. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434–57.
  3. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222–6. [CrossRef] Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977–82. [CrossRef] Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993–7. [CrossRef] Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, et al; Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90:1316–21.
  4. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512–8. [CrossRef] Kernt M, Welge-Lüssen U, Yu A, Neubauer AS, Kampik A. Bevacizumab is not toxic to human anteri